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Abstract
We propose a mathematical model based on probability theory to optimize COVID-19 testing
by a multi-step batch testing approach with variable batch sizes. This model and simulation tool
dramatically increase the efficiency and efficacy of the tests in a large population at a low cost.
The proposed method combines statistical modeling with numerical methods to solve nonlinear
equations and obtain optimal batch sizes at each step of tests, with the flexibility to incorporate
geographic and demographic information. We also conducted a Monte Carlo simulation study to
verify this theory. Our simulation results show that our method reduces the false negative rate
by 80%. Our method substantially improves the false positive rate and positive predictive value
as well. The proposed method will be particularly useful for the prevention of a second wave
of the coronavirus outbreaks, and more generally for the early stages of future pandemics. The
proposed work will have broader impacts on medical testing for contagious diseases in general.
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1 Introduction
To fight the COVID-19 pandemic with limited resources, batch tests are recommended by pooling
multiple swab samples from each individual. Samples from different individuals are pooled into one
batch and then a high-throughput PCR test is conducted (Cheng, 2020; Clark, 2020; Lohse et al.,
2020; Shani-Narkiss et al., 2020). By grouping individuals, batch testing significantly reduces the
number of tests, providing an efficient method to detect community transmission (Hogan et al.,
2020). Batch testing has become more relevant recently, as state and local governments seek to test
as many people as possible to transition safely back to normal life. For example, a recent press
release by the US FDA indicates developers’ interest in incorporating pooling samples for domestic
testing (Shuren, 2020). According to a CNN report, Dr. Anthony Fauci of the National Institute
of Allergy and Infectious Diseases said that The White House coronavirus task force was seriously
considering pooled testing for COVID-19 and acknowledged that the current testing strategy has
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proven inadequate (Acosta and Fossum, 2020). Places abroad such as South Korea started using
pooling methods to sample in batches of a fixed size in high-risk communities (Park and Koo, 2020;
Kwak, 2020; Korea Center for Disease Control & Prevention, 2020). However, the drawback to
batch testing is a much higher false negative rate than individual testing.
In this study, we introduce a batch-based approach which simultaneously addresses the problem
of limited resources and testing accuracy. We consider a multi-step testing procedure with variable
batch sizes where each step divides the population into subpopulations based on the previous step’s
results. These subpopulations are further divided into batches for testing. We introduce a method
to estimate the optimal batch sizes given the infection rates of subpopulations to efficiently and
accurately test most, if not the entire, population. The proposed method incorporates test errors
and optimizes batch sizes at each step and for each subpopulation. Shani-Narkiss et al. (2020)
also considered a multi-step testing procedure with variable batch sizes. However, their approach
assumes that there are no test errors, and their batch sizes are restricted to powers of two.
We recommend taking multiple test samples from each person in a single visit. The first sample
will be included in a batch PCR test. The samples are then split into subpopulations with negative
test results (batch negative) and positive test results (batch positive). Each subpopulation is given
another round of batch tests where the batch size increases for the batch negatives and decreases
for the batch positives. We iterate this procedure on each subpopulation, where at each step we
can estimate the infection rate. This process is continued until one of the following conditions is
satisfied: (i) the process results in three batch negatives or three batch positives, (ii) the infection
rate of the subpopulation becomes higher than 30%, (iii) the optimal batch size is reduced to 2.
Details of this procedure are given in Section 2.5. To apply our approach most effectively, we can
first divide the population based on infection rates, for example by dividing based on geography,
population density, proximity to highly infected regions, etc. Information given by various methods
including mobile apps and online mapping (Lee and Lee, 2020) may help track the virus and divide
the population into different groups.
We also address the efficacy of the tests. The false negative rate of the COVID-19 PCR test
for an individual is known to be near 15%, ranging from 10 to 30% (Clark, 2020; Xiao et al., 2020;
West et al., 2020; Yang and Yan, 2020). By one-step batch testing, the false negative rate increases
(Shuren, 2020). By our multi-step batch testing procedure, the false negative rate is substantially
reduced. To the best of our knowledge, no other studies have attempted estimating optimal batch
sizes by taking testing errors into account.
If three batch negatives occur before getting three batch positives, then we conclude that the
individuals in the batch of the final round are not infected. For people whose samples result in three
batch positives before three batch negatives, each sample needs to be tested individually to find out
which was positive. To reduce the false negative rate, up to three individual tests are performed for
the samples from each individual in this group. For a population of size 100,000 with an infection
rate of .1%, if the false negative rate is 15% and false positive rate is 1% for an individual test,
then our method requires less than 7,000 tests to test the entire population. Results for different
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infection rates are detailed in Section 3. The simulation results show that our method reduces the
false negative rate to approximately 3%, and the false positive rate to near zero.
It is a well-known fact that the positive predictive value (PPV) is very low when the infection
rate is low even if the sensitivity is very high. For a false positive rate of 1% and false negative rate
of 15%, the PPV of an individual test is 8% for an infection rate of .1%, and 46% for an infection
rate of 1%. According to our simulation, our multi-step batch testing procedure improves the PPV
to 89% and 93%, respectively. This is because individual tests are conducted on the subject in the
final positive batches which have higher infection rates than the entire population (see Section 2.4
and Section 3).
The original purpose for batch testing was to prevent the spread of disease in high-risk commu-
nities by testing everyone, symptomatic or not. However, the proposed method can be applied to
the general population, due to its flexibility in dealing with various infection rates and its substan-
tially greater sensitivity compared to individual testing and current batch testing approaches. More
specifically, our method can accurately test a large population with limited resources by dividing the
population based on infection rates, for example based on geography, population density, proximity
to highly infected regions, etc. This method can be applied to effectively combat a second wave of
the current pandemic and even a future pandemic of new diseases.
2 Mathematical Model
2.1 Optimal batch size assuming no testing errors
We begin by studying a simple case where the accuracy of a virus screening test is 100%. Suppose
that the infection rate in a population is p (rate of no infection is q = 1 − p) and the accuracy of
a virus screening test is 100%. Let X be a random variable denoting the number of positive cases
in a batch of size n. Then X follows a binomial distribution with n trials and success rate p. The
probability of k positive cases in the batch is
P (X = k) =
(
n
k
)
pk(1− p)n−k, k = 0, · · · , n (1)
and the probability that the batch is tested negative is P (X = 0) = (1− p)n = qn.
Using an initial guess of the batch size n, we want to estimate q. Let A = P (X = 0). Then after
a good number of batch tests, we can estimate q by
A ≡ qn =⇒ q = A1/n.
Suppose we test a population in batches of size n, then test all individuals who were in positively
tested batches. For a population of size N , the expected total number of tests to be performed to
3
identify all positive carriers is
T (n) =
N
n
+ n (1− qn)
N
n
=
N
n
+N (1− qn) = N
(
1
n
+ 1− qn
)
. (2)
To find the optimal n, we minimize T (n) as
T ′(n) = N
(
−
1
n2
− qn ln q
)
= 0 =⇒−
1
n2
= qn ln q
∴ n2qn ln q = −1
We can solve this equation for n numerically.
2.2 Optimal batch size given testing errors
We conduct a hypothesis testing with null hypothesis H0: The subject is healthy versus alterna-
tive hypothesis H1: The subject is infected. To reduce testing errors, we propose a procedure of
conducting multiple rounds of batch tests before carrying out individual tests for a selected group.
Denote the probability of a Type I error (false positive rate) as α and the probability of a Type II
error (false negative rate) as β. Let the infection rate be p1 and q1 = 1 − p1 in the initial batch
tests for the whole population, and X the random variable denoting the number of positive cases in
a batch of size n1. Then the probability of a batch negative based on (1) can be obtained as
(1− α)P (X = 0) + βP (X > 0) = (1− α)qn11 + β (1− q
n1
1 ) = (1− α− β)q
n1
1 + β. (3)
Using an initial guess of the batch size n1, we want to estimate q1. After a good number of batch
tests, we can estimate q1 by
A1 ≡ (1− α− β)q
n1
1 + β =⇒ q1 =
(
A1 − β
1− α− β
)1/n1
. (4)
Suppose all the subjects in the positive batches get individual PCR tests. If the size of the entire
population is N1, the required number of tests can be obtained from (2) by substituting (3) for q
n
as
T1(n1) = N1
[
1
n1
+ 1−A1
]
= N1
[
1
n1
+ 1− β − (1− α− β)qn11
]
. (5)
To find the optimal batch size x, we minimize T1(x) as
T ′1(x) = N1
[
−
1
x2
− (1− α− β)qx1 ln q1
]
= 0 =⇒ xq
x/2
1 = [−(1− α− β) ln q1]
−1/2.
This can be solved for x numerically. In this study, we used the secant method to solve the equation.
The optimal batch size n1 is either floor(x) or ceiling(x) which has the lower value of T (·). The
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initial batch tests can be conducted using n1 for the whole population.
Continuing this process, after the (i− 1)th round, the subjects have been divided into subpopu-
lations. Each subpopulation was batch tested with batch sizes determined from that round. Fixing
one of these subpopulations, we now split it into two smaller subpopulations for the ith round, ac-
cording to the batch test results from the (i− 1)th round. Let Ni denote the number of subjects in
population belonging to test-negative batches from the (i− 1)th round, and pi denote the infection
rate of this subpopulation. The expected size of the subpopulation in the ith round of batch tests is
Ni = Ni−1
[
(1− α− β)q
ni−1
i−1 + β
]
. (6)
In this subpopulation, the probability that at least one subject in a batch is infected is
ri ≡
β
(
1− q
ni−1
i−1
)
(1− α)q
ni−1
i−1 + β
(
1− q
ni−1
i−1
) (7)
and the probability that all the subjects in a batch are not infected is 1− ri. The estimated number
of infected subjects in this subpopulation is
mi ≡
Ni
ni−1
· ri ·
E(Xi−1)
P (Xi−1 > 0)
=
Ni
ni−1
· ri ·
ni−1pi−1
1− q
ni−1
i−1
=
Nipi−1ri
1− q
ni−1
i−1
.
Here, E(Xi−1)/P (Xi−1 > 0) is the expected number of infected subjects in a test-positive batch in
the (i−1)th round, where Xi−1 is a binomial random variable with ni−1 trials and success rate pi−1.
Therefore, the infection rate
pi =
mi
Ni
=
pi−1ri
1− q
ni−1
i−1
(8)
of the subpopulation in the ith round can be used for estimating the optimal batch size and the
required number of tests. The optimal number of required tests can be obtained by replacing n1
with ni and q1 with qi in (3) and (5) to get
Ti(ni) = Ni
[
1
ni
+ 1− β − (1− α− β)qnii
]
(9)
and the optimal batch size for this round is obtained by minimizing Ti(·).
For example, suppose the estimated infection rate is p1 = .01 and α = .01, β = .15 for the
population of size 100,000. Then T1(x) in (5) is minimized when n1 = 12. For the second round, the
expected subpopulation size is obtained from (6) as N2 = 100, 000
[
.84(.99)12 + .15
]
= 89,456. From
(7), r2 = .15
[
1− (.99)12
]
/
{
(1− .01)(.99)12 + 0.15
[
1− (.99)12
]}
= .019 and the estimated infection
rate in this subpopulation is obtained from (8) as p2 = (.01)(.019)/
[
1− (.99)12
]
= 0.00167. For this
infection rate, the optimal batch size n2 = 27 is obtained by minimizing T2(x) in (9).
Further, we can estimate the optimal batch size for the subpopulation consisting of batch posi-
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Figure 1: Optimal batch size (left) and required number of batches (right) for the first round of
batch tests. False positive rate: .01, population size: 100,000.
tives. In the (i− 1)th round, the probability that a batch of size ni−1 is tested positive is
αP (X = 0) + (1− β)P (X > 0) = αqni−1 + (1− β) (1− qni−1) = (1− β)− (1− α− β)qni−1 .
The size of this subpopulation can be modified from (6) as
Ni = Ni−1
[
(1− β)− (1− α− β)q
ni−1
i−1
]
.
In this subpopulation, the probability that at least one subject in a batch is infected is
ri ≡
(1− β) (1− qni−1)
αqni−1 + (1− β) (1− qni−1)
and the probability that all the subjects are not infected is 1− ri. The estimated infection rate pi
in this subpopulation can be obtained as (8). This infection rate can be used for estimating the
optimal batch size ni and the required number of tests for the subpopulation in the ith round. The
accuracy of these formulae developed in this section has been confirmed by matching results with
the simulation results given in Section 3.
Figure 1 displays the optimal batch size and the required number of batches for a population of
size 100,000 as the infection rate ranges from .001 to .25 for the first round, and the false negative
rate ranges from .1 to .25. The false positive rate is fixed at .01. Table 1 displays the optimal batch
sizes for different infection rates (a) when no testing errors are assumed and (b) when the false
negative rate is 15% and the false positive rate is 1%.
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Table 1: Optimal batch size (a) when there are no testing errors, and (b) when the false negative
rate is .15, false positive rate is .01.
p∗ .001 .002 .003 .004 .005 .006 .007 .008 .009 .01 .02 .03
(a) 32 23 19 16 15 13 12 12 11 11 8 6
(b) 35 25 21 18 16 15 14 13 12 12 8 7
p .04 .05 .06 .07 .08 .09 to .12 .13 to .17 .18 to .25
(a) 6 5 5 4 4 4 3 3
(b) 6 6 5 5 5 4 4 3
∗Infection rate
Table 2: Probability in each cell of the confusion matrix for single batch testing.
True condition
No samples are infected At least one sample is infected
Test − (a) (1− α)P (X = 0) (b) βP (X > 0)
Result + (c) αP (X = 0) (d) (1 − β)P (X > 0)
2.3 Sensitivity and specificity of a batch test
Let us consider one-step batch testing. If a batch is tested negative, then we conclude that all
samples in the batch are negative. If a batch is tested positive, then each sample in the batch needs
to be tested individually. Let the binomial random variable X denote the number of positive cases
for a batch of size n with an infection rate of p. We continue to denote α as the probability of a
Type I error and β as the probability of a Type II error for an individual test. Table 2 displays the
probabilities for the confusion matrix.
2.3.1 Sensitivity
In cells (b) and (d), at least one sample is infected in each batch. It can be deduced that all the
samples in cell (b) are negative, and no more tests are given. The probability that an infected
individual is incorrectly tested negative from the batch test is βP (X > 0)[p/P (X > 0)] = βp. In
cell (d), the probability that an infected individual is correctly tested positive from the batch test
is (1− β)P (X > 0)[p/P (X > 0)] = (1− β)p. An individual test is given to each sample in this cell,
and the probability that a sample is incorrectly tested negative is β(1−β)P (X > 0)[p/P (X > 0)] =
β(1− β)p. Therefore, the false negative rate is obtained as
βp+ β(1− β)p
βp+ (1− β)p
=
βp+ β(1− β)p
p
= β(2− β).
For example, if β = .15, then the false negative rate of batch testing is .85(2− .85) = .2775, and
thus the sensitivity is .7225. Note that the false negative rate of a batch test depends on neither the
infection rate nor the batch size. The above result is supported by our simulation results given in
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Table 3: Specificity for single batch testing with fixed batch size of 10 and optimal batch sizes when
the false negative rate is .15, and the false positive rate is .01.
Infection rate .001 .01 .03 .05 .01
Batch size 10 Specificity .9990 .9983 .9970 .9960 .9941
Optimal Batch size 35 12 7 5 4
batch size Specificity .9968 .9980 .9978 .9977 .9968
Section 3. It confirms that the sensitivity is decreased by conventional batch testing. In contrast, our
multi-step batch testing method has a significantly higher sensitivity than conventional individual
tests as well as single batch testing according to our simulation studies.
2.3.2 Specificity
Uninfected samples can be in any of the four cells in Table 2. However, the errors from cells (c) and
(d) are considered for calculating the specificity since they are tested positive, and the samples in
these cells go through individual tests. From the individual tests, the probability that a sample is
incorrectly tested positive is αP (X = 0) [1− (1− α)n] in cell (c), and α(1 − β)(1 − p)P (X > 0) in
cell (d). Therefore, the false positive rate of batch testing is
α {P (X = 0) [1− (1− α)n] + (1− β)(1 − p)P (X > 0)}
1− p
. (10)
Unlike the sensitivity of batch testing, the batch size, infection rate, probability of a Type I error,
and probability of a Type II error contribute to (10). For α = .01 and β = .15, the specificity of
batch testing (1 minus (10)) using a fixed batch size of 10, and using the optimal batch sizes is given
in Table 3.
The specificity is improved by batch testing when the infection rate is 1% or higher. For the
infection rate of .1%, the specificity does not improve when a fixed batch size of 10 is used, and it
decreases when the optimal batch size of 35 is used. This may be because all the samples in a positive
batch with a large size go through individual testing, and thus the chance of false positive increases.
However, our multi-step batch testing significantly improves the specificity from the individual tests
even for the infection rate of .1% according to our simulation studies.
2.4 PPV and NPV
Let us define E as the event that an individual is infected by the virus, and B as the event that an
individual got a positive test result. Then by the Bayes’ Rule, PPV (positive predictive value: an
individual is infected given a positive test result) is
P (E|B) =
P (B|E)P (E)
P (B|E)P (E) + P (B|EC)P (EC)
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Table 4: PPV and NPV.
Sensitivity(1)
p(2) .75 .77 .79 .81 .83 .85 .87 .89 .90
.001 PPV .0070 .0072 .0073 .0075 .0077 .0078 .0080 .0082 .0083
NPV .9997 .9998 .9998 .9998 .9998 .9998 .9999 .9999 .9999
.002 PPV .1307 .1337 .1367 .1397 .1426 .1455 .1485 .1514 .1528
NPV .9995 .9995 .9996 .9996 .9997 .9997 .9997 .9998 .9998
.004 PPV .2315 .2362 .2409 .2455 .2500 .2545 .2589 .2633 .2655
NPV .9990 .9991 .9991 .9992 .9993 .9994 .9995 .9996 .9996
.006 PPV .3116 .3173 .3229 .3284 .3338 .3391 .3443 .3495 .3520
NPV .9985 .9986 .9987 .9988 .9990 .9991 .9992 .9993 .9994
.008 PPV .3769 .3831 .3892 .3951 .4010 .4067 .4123 .4178 .4206
NPV .9980 .9981 .9983 .9985 .9986 .9988 .9989 .9991 .9992
.01 PPV .4310 .4375 .4438 .5500 .4560 .4620 .4677 .4734 .4762
NPV .9975 .9977 .9979 .9981 .9983 .9985 .9987 .9989 .9990
.02 PPV .6048 .6111 .6172 .6231 .6288 .6343 .6397 .6449 .6475
NPV .9949 .9953 .9957 .9961 .9965 .9969 .9973 .9977 .9979
.03 PPV .6988 .7043 .7096 .7147 .7197 .7244 .7291 .7335 .7357
NPV .9923 .9929 .9935 .9941 .9947 .9953 .9960 .9966 .9969
.05 PPV .7978 .8021 .8061 .8100 .8137 .8173 .8208 .8241 .8257
NPV .9869 .9879 .9890 .9900 .9910 .9921 .9931 .9942 .9947
.08 PPV .8671 .8701 .8729 .8757 .8783 .8808 .8832 .8856 .8867
NPV .9785 .9802 .9819 .9836 .9853 .9870 .9887 .9904 .9913
.10 PPV .8929 .8953 .8978 .9000 .9022 .9043 .9063 .9082 .9091
NPV .9727 .9748 .9770 .9791 .9813 .9834 .9856 .9878 .9889
.15 PPV .9298 .9315 .9331 .9346 .9361 .9375 .9388 .9401 .9408
NPV .9573 .9606 .0639 .9672 .9706 .9740 .9774 .9808 .9825
.20 PPV .9494 .9506 .9518 .9529 .9540 .9551 .9560 .9570 .9574
NPV .9406 .9451 .9496 .9542 .9588 .9635 .9682 .9730 .9754
(1)Specificity is .99 (2)Infection rate
and NPV (negative predictive value: an individual is not infected given a negative test result) is
P
(
EC |BC
)
=
P
(
BC |EC
)
P
(
EC
)
P (BC |EC)P (EC) + P (BC |E)P (E)
.
For example, if the infection rate in the population is 1%, sensitivity is 85%, and specificity is 99%,
then P (E) = 0.01, P (B|E) = 0.85 and P
(
BC |EC
)
= 0.99. Therefore, the PPV is .4620 and the
NPV is .9985. If the infection rate is .1%, then the PPV is .0078 and the NPV is .9998. For
the infection rates p ∈ [.001, .2], sensitivity within the range of [.75, .90] and the specificity of .99,
Table 4 illustrates PPV and NPV. Figure 2 displays the PPV (above) and NPV (below). The PPV
is substantially improved by our multi-step batch testing procedure (see Section 3).
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Figure 2: PPV (above) and NPV (below).
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Figure 3: Proposed multi-step batch testing procedure. The oval nodes indicate intermediate nodes
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2.5 Multi-step batch testing procedure
More than 3 batch negatives may not be necessary in the procedure because the infection rate
substantially decreases in later rounds. Figure 3 illustrates the proposed batch test procedure. We
will further investigate the optimal number of batch tests and the stopping rule in this study. For
batch negatives, the batch size increases substantially with most of the subjects remaining in the next
round because the infection rate decreases. For batch positives, the subpopulation size substantially
decreases in the next round. In this group, not all the samples in the batch are infected, so we can
find a sample without infection in the next round of batch tests. This way, the number of required
tests to cover the whole population decreases significantly. It is possible to identify all positive
carriers in the population if a sufficient number of swab samples can be obtained from each person
in a single visit.
We assume 15% false negative rate and 1% false positive rate of an individual for a population
of size 100,000 in this section. Table 5 shows the change in the infection rate and corresponding
optimal batch size throughout the process shown in Figure 3 for a population with infection rates
of .1% and 1%. In the first round, the optimal batch size is 35 resulting in 2,858 batch tests when
the infection rate is .1%, and the optimal batch size is 12 resulting in 8,334 batch tests when the
infection rate is 1%. Note that the number of batch tests for the first round can be slightly different
from this estimation due to the trial for estimating the infection rate with (4) using a small subset
of the population with an initial guess of the batch size. The subsequent rounds do not require
this trial because the infection rates of subpopulations can be estimated as (8) using the values
obtained in the previous rounds. For the ith round, the number of batch tests can be obtained by
ceiling(Ni/ni). We count only the bold-faced numbers starting the first round because the rest are
duplicates. In each of Round 2 and Round 3, the bold-faced subpopulation sizes (Ni) add up to
100,000 if we ignore the rounding error. In Round 4, the bold-faced subpopulation sizes plus N in
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the final column for already finished (−−− and +++) rows add up to 100,000. The calculation is
similar for Round 5. The final two columns show the infection rate and resulting subpopulation size
in each of the terminal nodes (rectangular frames) in Figure 3. For each infection rate, since the
individuals in an upper half of the last column got 3 batch negatives, they do not need individual
tests. A lower half of the last column needs individual tests because they got 3 batch positives.
Thus, the total number of individual tests is the sum of these 10 numbers. The total number of
tests can be obtained by adding the number of batch tests in Round 1, the number of batch tests
obtained from the bold-faced numbers in the subsequent rounds, and the number of individual tests.
The expected number of tests to identify all positive carriers is 6,144 (5,696 batch tests and 448
individual tests) when the infection rate is .1%, and 22,436 (19,409 batch tests and 3,027 individual
tests) when the infection rate is 1%. To reduce the false negative rate, we propose to conduct
simultaneous tests for three samples from each individual in the group of 3 batch positives. Then
the number of individual tests is 3 times the sum of the 10 numbers at the bottom of the last column.
The decision is made by majority voting. After these simultaneous individual tests, the expected
number of tests becomes 7,040 when the infection rate is .1% and 28,490 when the infection rate is
1%.
To preserve testing resources, the simultaneous individual tests can be modified as sequential
individual tests as follows: We conduct up to 3 tests for the same person sequentially until a positive
test occurs. Let us define E as the event that an individual is infected by the virus, and Bi as the
event that an individual got a positive result in the ith individual test. Then the probability that
a sample is tested positive in the first test is
p1 ≡ P (B1) = P (B1|E)P (E) + P
(
B1|E
C
)
P
(
EC
)
,
the probability that a person is tested negative and then tested positive is
p2 ≡ P
(
BC1 ∩B2
)
= P
(
BC1 ∩B2|E
)
P (E) + P
(
BC1 ∩B2|E
C
)
P
(
EC
)
and a person is tested negative twice is
p3 ≡ P
(
BC1 ∩B
C
2
)
= P
(
BC1 ∩B
C
2 |E
)
P (E) + P
(
BC1 ∩B
C
2 |E
C
)
P
(
EC
)
.
Thus, the expected number of the individual tests for each person is
p1 + 2p2 + 3p3. (11)
We can obtain the expected total number of sequential individual tests by substituting the infection
rate and the subpopulation size in each of the bottom 10 rows of the last two columns. For the
infection rate of .1%, the expected number of sequential individual tests in (11) is 1,155, and the
expected number of tests for the whole procedure becomes 6,851. For the infection rate of 1%, the
expected number of sequential individual tests is 7,236, and the expected number of tests for the
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Table 5: Batch test procedure∗: population size 100,000, false negative rate 15% & false positive
rate 1% for individual tests, infection rates .1% and 1%.
Infection rate= .1%. The first round requires 2858 tests with batch size 35.
Round 2 Round 3 Round 4 Round 5 Final
Tests p
(1)
2 N
(2)
2 n
(3)
2 p3 N3 n3 p4 N4 n4 p5 N5 n5 p N
−−− 2e-4 96109 88 2e-5 94047 224 4e-6 92684
−−+− 2e-4 96109 88 2e-5 94047 224 .001 1363 30 2e-4 1302
−+−− 2e-4 96109 88 .006 2062 15 .001 1888 35 2e-4 1814
+−−− .022 3891 8 .004 3322 18 6e-4 3102 45 e-4 3000
−−++− 2e-4 96109 88 2e-5 94047 224 .001 1363 30 .027 61 7 .005 51
−+−+− 2e-4 96109 88 .006 2062 15 .001 1888 35 .022 74 8 .004 63
−++−− 2e-4 96109 88 .006 2062 15 .062 175 5 .012 133 10 .002 118
+−−+− .022 3891 8 .004 3322 18 6e-4 3102 45 .016 102 9 .003 90
+−+−− .022 3891 8 .004 3322 18 .049 220 6 .010 169 12 .002 152
+ +−−− .022 3891 8 .13 568 4 .03 362 7 .005 300 15 .001 278
+ + + .022 3891 8 .13 568 4 .30 206
+ +−+ .022 3891 8 .13 568 4 .03 362 7 .15 62
+−++ .022 3891 8 .004 3322 18 .049 220 6 .18 51
−+++ 2e-4 96109 88 .006 2062 15 .062 175 5 .22 42
+ +−−+ .022 3891 8 .13 568 4 .03 362 7 .005 300 15 .06 23
+−+−+ .022 3891 8 .004 3322 18 .049 220 6 .010 169 12 .08 17
+−−++ .022 3891 8 .004 3322 18 6e-4 3102 45 .016 102 9 .11 13
−++−+ 2e-4 96109 88 .006 2062 15 .062 175 5 .012 133 10 .10 14
−+−++ 2e-4 96109 88 .006 2062 15 .001 1888 35 .022 74 8 .13 11
−−+++ 2e-4 96109 88 2e-5 94047 224 .001 1363 30 .027 61 7 .15 9
Infection rate= 1%. The first round requires 8335 tests with batch size 12.
Round 2 Round 3 Round 4 Round 5 Final
Tests p2 N2 n2 p3 N3 n3 p4 N4 n4 p5 N5 n5 p N
−−− .002 89456 27 3e-4 85233 68 4e-5 83107
−−+− .002 89456 27 3e-4 85233 68 .009 2126 12 .0015 1921
−+−− .002 89456 27 .03 4223 7 .006 3496 15 .0009 3229
+−−− .08 10544 5 .017 7399 9 .003 6425 21 .0005 6033
−−++− .002 89456 27 3e-4 85233 68 .009 2126 12 .079 205 5 .017 144
−+−+− .002 89456 27 .03 4223 7 .006 3496 15 .061 267 5 .012 204
−++−− .002 89456 27 .03 4223 7 .15 727 4 .038 430 6 .007 351
+−−+− .08 10544 5 .017 7399 9 .003 6425 21 .041 392 6 .008 314
+−+−− .08 10544 5 .017 7399 9 .11 974 4 .025 657 8 .0044 550
+ +−−− .08 10544 5 .23 3144 3 .065 1679 5 .013 1262 10 .0022 1120
+ + + .08 10544 5 .23 3144 3 .42 1466
+ +−+ .08 10544 5 .23 3144 3 .065 1679 5 .22 417
+−++ .08 10544 5 .017 7399 9 .11 974 4 .29 317
−+++ .002 89456 27 .03 4223 7 .15 727 4 .31 298
+ +−−+ .08 10544 5 .23 3144 3 .065 1679 5 .013 1262 10 .10 142
+−+−+ .08 10544 5 .017 7399 9 .11 974 4 .025 657 8 .13 107
+−−++ .08 10544 5 .017 7399 9 .003 6425 21 .041 392 6 .18 78
−++−+ .002 89456 27 .03 4223 7 .15 727 4 .038 430 6 .18 79
−+−++ .002 89456 27 .03 4223 7 .006 3496 15 .061 267 5 .22 63
−−+++ .002 89456 27 3e-4 85233 68 .009 2126 12 .079 205 5 .23 60
(1)infection rate (2)subpopulation size (3)batch size
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whole procedure is 26,645. If the test results are not time sensitive, then the sequential tests are
preferred to the simultaneous tests.
3 Simulation Studies
We conducted a Monte Carlo simulation study to evaluate the efficiency and efficacy of the proposed
batch testing procedure. In this simulation, we assume that the sensitivity and specificity of tests
are 85% and 99%, respectively. A population of 100,000 people is randomly generated 100 times.
The infection rates of .1%, 1%, 3%, 5% and 10% are chosen. Table 6 compares our methods with
conventional individual tests as well as single batch testing using various accuracy measures. We
compare the accuracy measures for (A) conventional individual tests, (B) one-step batch testing
with a fixed batch size of 10, (C) one-step batch testing with optimal batch sizes as proposed in
this study, (D) proposed multi-step batch tests ending with three batch negatives or three batch
positives, with an individual test given to three batch positives, (E) our multi-step batch tests given
in (D), with 3 simultaneous individual tests for three batch positives, (F) our multi-step batch tests
given in (D), with up to 3 individual tests for three batch positives. In (E), the decision for the
simultaneous individual tests is made by majority voting. For (C), (D), (E) and (F), the optimal
batch sizes estimated in Section 2.5 are used in the subpopulations in each step. For each of the
infection rates, the overall accuracy, sensitivity, specificity, PPV and NPV are calculated, and the
required number of tests to cover the whole population is calculated from this simulation, and the
values are averaged over the 100 repetitions. The fixed batch size of 10 given in (B) has been used
in South Korea for high-risk facilities. For multi-step batch testing, individual tests are conducted
to the subpopulation if the infection rate exceeds 30% in any step as mentioned in Section 1.
The accuracy measures of methods (B) and (C) are very close. However, (C) requires fewer
tests by using the optimal batch sizes. Note that the number of required tests in methods (D), (E)
and (F) are close to the estimated numbers derived in Section 2.5. The sensitivity is reduced in
the single batch tests (given in (B) and (C)) to approximately 72% from conventional individual
tests. This is because if a batch is tested negative, then all the samples in the batch are considered
uninfected, and no further tests are given. The results are in line with the sensitivity of 72.25%
for one-step batch testing obtained in Section 2.3.1. By the multi-step batch testing given in (D),
the sensitivity is substantially improved from the single batch tests to approximately 83%. After
conducting simultaneous individual tests for the 3 batch positives (given in (E)), the sensitive is
increased to over 91%, and sequential individual tests in (F) further improves it to approximately
97%. This improvement is achieved because the simultaneous tests or sequential individual tests are
given to small target subpopulations obtained by our test procedure. As mentioned in Section 2.3.2,
the specificity is improved by single batch testing from conventional individual testing when the
infection rate is 1% or higher, but it is not improved when the infection rate is .1%. However, we
can see from (E) and (F) that our multi-step batch testing significantly improves the sensitivity
across the whole range of the infection rates. The specificity of single batch testing obtained in
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Table 6: Simulation results: 100 repetitions, population size 100,000, sensitivity 85% & specificity
99% for individual tests; mean with standard deviation in parentheses.
p(1) .001 .01 .03 .05 .10
(A)a Acc.(2) .9899 (.0003) .9886 (.0004) .9858 (.0003) .9830 (.0004) .9760 (.0005)
Indiv. Sens.(3) .8519 (.0365) .8493 (.0112) .8504 (.0060) .8494 (.0046) .8503 (.0035)
Tests Spec.(4) .9900 (.0003) .9900 (.0003) .9900 (.0003) .9900 (.0003) .9900 (.0004)
PPV .0787 (.0083) .4627 (.0128) .7247 (.0075) .8168 (.0051) .9045 (.0032)
NPV .9999 (.0000) .9985 (.0001) .9953 (.0002) .9921 (.0003) .9835 (.0004)
#Tests(5) 100,000 (0) 100,000 (0) 100,000 (0) 100,000 (0) 100,000 (0)
(B)b Acc. .9996 (.0001) .9964 (.0002) .9896 (.0004) .9831 (.0004) .9675 (.0007)
Single Sens. .7305 (.0452) .7237 (.0131) .7223 (.0088) .7226 (.0078) .7229 (.0057)
Batch Spec. .9998 (.0000) .9992 (.0001) .9979 (.0002) .9968 (.0002) .9947 (.0002)
Tests PPV .8143 (.0376) .8995 (.0111) .9148 (.0058) .9222 (.0043) .9386 (.0026)
Fixed NPV .9997 (.0001) .9972 (.0002) .9914 (.0003) .9856 (.0004) .9700 (.0007)
Size 10 #Tests 11,832 (146) 19,041 (297) 33,117 (377) 44,646 (472) 65,771 (459)
(C)c Acc. .9993 (.0001) .9962 (.0002) .9902 (.0003) .9843 (.0004) .9700 (.0006)
Single Sens. .7218 (.0471) .7198 (.0146) .7226 (.0066) .7226 (.0065) .7218 (.0051)
Batch Spec. .9996 (.0001) .9990 (.0001) .9985 (.0001) .9980 (.0001) .9976 (.0002)
Tests PPV .6526 (.0401) .8800 (.0114) .9371 (.0050) .9508 (.0034) .9712 (.0019)
Variable NPV .9997 (.0001) .9972 (.0002) .9915 (.0002) .9856 (.0004) .9699 (.0006)
Sizes #Tests 6,732 (359) 18,888 (358) 31,469 (310) 39,935 (380) 54,897 (284)
B+Ind(6) 2858+3874 8334+10554 14186+17283 16668+23267 25000+29897
(D)d Acc. .9998 (.0000) .9980 (.0001) .9941 (.0002) .9906 (.0003) .9814 (.0004)
Multi- Sens. .8238 (.0385) .8263 (.0115) .8292 (.0067) .8306 (.0056) .8297 (.0036)
Step Spec. 1.000 (.0000) .9998 (.0000) .9992 (.0001) .9990 (.0001) .9983 (.0001)
Batch PPV .9574 (.0227) .9716 (.0055) .9704 (.0035) .9772 (.0022) .9817 (.0015)
Tests NPV .9998 (.0000) .9982 (.0001) .9947 (.0002) .9912 (.0003) .9814 (.0004)
#Tests 6,219 (164) 22,935 (293) 42,580 (300) 56,099 (328) 83,989 (399)
B+Ind 5710+509 19495+3440 31832+10748 41553+14546 58617+25372
(E)e Acc. .9999 (.0000) .9991 (.0001) .9974 (.0002) .9958 (.0002) .9916 (.0003)
(D) with Sens. .9122 (.0306) .9158 (.0095) .9160 (.0057) .9164 (.0038) .9165 (.0025)
Simul. Spec. 1.0000 (.0000) 1.000 (.0000) 1.0000 (.0000) 1.0000 (.0000) .9999 (.0000)
Indiv. PPV .9980 (.0043) .9993 (.0009) .9991 (.0006) .9994 (.0003) .9995 (.0002)
Tests NPV .9999 (.0000) .9991 (.0001) .9974 (.0002) .9956 (.0002) .9908 (.0003)
for 3 +’s #Tests 7,224 (259) 29,794 (507) 64,087 (651) 85,191 (699) 134,774 (923)
B+Ind 5700+1524 19489+10305 31825+32262 41560+43631 58626+76148
(F)f Acc. .9999 (.0000) .9990 (.0001) .9969 (.0002) .9958 (.0002) .9926 (.0003)
(D) w/ Sens. .9710 (.0170) .9697 (.0049) .9725 (.0029) .9727 (.0025) .9727 (.0019)
Seq. Spec. .9999 (.0000) .9993 (.0001) .9976 (.0002) .9970 (.0002) .9948 (.0003)
Indiv. PPV .8919 (.0296) .9309 (.0081) .9272 (.0044) .9449 (.0032) .9543 (.0023)
Tests NPV 1.000 (.0000) .9997 (.0000) .9991 (.0001) .9986 (.0001) .9970 (.0002)
for 3 +’s #Tests 7,040 (231) 27,928 (474) 58,476 (583) 75,990 (561) 116,445 (728)
B+Ind 5704+1336 19487+8441 31838+26638 41544+34446 58625+57820
aConventional individual tests
bOne-step batch tests with a fixed batch size of 10, individual tests for positive batches
cOne-step batch tests with variable optimal batch sizes; individual tests for positive batches
dMulti-step batch tests ending with 3 batch negatives or 3 batch positives; individual tests for 3 batch positives
e (D) with 3 simultaneous individual tests with majority voting for 3 batch positives.
f (D) with maximum 3 sequential individual tests until getting a positive test
(1)infection rate (2)overall accuracy (3)sensitivity (4)specificity (5)Number of required tests
(6)number of batch tests + number of individual tests
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this simulation is quite similar to the values given in Section 2.3.2 for infection rates higher than
1%, but they are quite different for lower infection rates. This may be due to randomness and
large batch sizes with mostly uninfected samples. More studies will be required to clearly explain
this discrepancy. According to our simulation, our multi-step batch testing improves the specificity
across the whole range of the infection rates.
The improvement of the PPV by our procedure is extraordinary. As discussed in Section 2.4
(also shown in (A) of Table 6), the PPV of an individual test is 8% and 46% when the infection
rates are .1% and 1%, respectively. According to our simulation, a single-step batch testing with
optimal batch sizes improves this to 65% and 88%, respectively. Our procedure shown in (F) further
improves it to 89% and 93%, respectively. Method (F) gives lower PPV, but higher sensitivity than
Method (E). This is tradeoff between simultaneous tests and sequential tests.
The overall number of batch tests from the simulation is close to the estimated number from
our model given in Section 2.2. For .1% infection rate, the number of batch tests in the simulation
is 5,700 and the estimated number is 5,696. For 1% infection rate, the numbers are 19,495 from
the simulation and 19,409 from our estimation. However, the simulated number of individual tests
for samples with 3 batch positives is slightly higher than the predicted value. This is likely due
to randomness. This discrepancy does not significantly impact the overall number of tests because
the size of the subpopulation requiring individual tests is very small (approximately 0.5% for .1%
infection rate, and around 3% for 1% infection rate) compared to the whole population. For .1%
infection rate, for example, 509 people received individual tests in the simulation (given in (D)),
whereas the model estimates that 448 people need individual tests. This means approximately
99.5% of the population do not require individual tests. The model estimate of this value is 99.552%
(100,000-448), and the simulated value is 99.491% (100,000-509).
Note that the overall accuracy is mostly affected by specificity because the infection rates are
low. We can incorporate geographic and demographic information for more realistic calculation.
4 Discussion
The COVID-19 pandemic changed our lifestyle, seriously impacted the global economy, and took
many precious lives. To get back to normalcy, or prevent a second wave of the disease, we need a
rapid testing of the virus for all the residents of each community. Unlike other coronavirus outbreaks
we experienced in the past, the disease rapidly spreads silently by asymptomatic carriers. Since only
patients with symptoms have been getting tests, it is a challenging task to identify asymptomatic
COVID-19 carriers. In most countries including the US, some patients with symptoms could not get
tests due to the limited testing capacity. To conduct testing a broader population more efficiently,
batch testing methods have been introduced.
The South Korean Center for Disease Control & Prevention used a single-step batch testing for
long-term care facilities with a fixed batch size of 10 for the entire staff and patients. As seen in our
simulation studies, batch testing increases the false negative rate, although this approach can monitor
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high-risk groups without symptoms by reducing the number of tests needed to cover the entire
community. In this paper, we proposed a multi-step batch testing procedure to substantially decrease
the false negative rate using a small number of test kits to completely test a large population. The
improvement of PPV from individual testing is also remarkable, thus our multi-step approach can
be trusted for reliable results. Note that the sampling portion of our procedure can be implemented
by taking multiple test samples obtained from each person in a single visit.
Table 5 shows that the proposed batch procedure is effective for a population with a low or mod-
erate infection rate. For the groups of 3 batch positives, we proposed 3 simultaneous or sequential
individual tests, depending on the speed of assessment and supply of testing resources. For example,
if the test results are delayed, then the simultaneous tests are recommended. If the test results can
be obtained fast enough, then the sequential tests will be more cost effective.
Our approach will be useful for the prevention of a second wave of coronavirus, and more generally
for early stages of future pandemics. Our method is most effective for diseases with infection rates of
up to 3%. We do not recommend this approach for highly contagious large populations with infection
rates greater than 5%, as the prescribed amount of tests becomes very large. Shuren (2020) addresses
that conventional batch testing has a higher chance of false negative results because samples are
diluted, but it works well when there is a low prevalence of cases. In contrast, our method is also
useful for moderate size, highly contagious communities which require accurate virus screening for
the entire community. In future studies, we will investigate optimal stopping rules to further improve
the efficiency and efficacy of the multi-step batch testing procedure.
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